Gauduin M C, Safrit J T, Weir R, Fung M S, Koup R A
Aaron Diamond AIDS Research Center, New York, NY 10016, USA.
J Infect Dis. 1995 May;171(5):1203-9. doi: 10.1093/infdis/171.5.1203.
Monoclonal antibody BAT123 was passively transferred into SCID mice reconstituted with human peripheral blood lymphocytes (hu-PBL-SCID) to study passive antibody protection against human immunodeficiency virus type 1 (HIV-1) infection. BAT123 is specific for the third variable loop of the gp120 of HIV-1LAI. Animals were protected against subsequent infection with LAI strain, but not other virus strains, when BAT123 (1 mg/kg; 25 micrograms/mouse) was given 1 h before virus inoculation. This resulted in a peak serum concentration of 16 micrograms/mL of the antibody, which should be easily attainable in humans. In addition, postexposure protection was observed when the antibody was given within 4 h of virus inoculation. No therapeutic effect was observed, however, when BAT123 was administered after infection had been established. These results indicate that passive antibody prophylaxis against HIV-1 infection may be possible in certain clinical situations.
将单克隆抗体BAT123被动转移至用人外周血淋巴细胞重建的严重联合免疫缺陷小鼠（hu-PBL-SCID）体内，以研究被动抗体对1型人类免疫缺陷病毒（HIV-1）感染的保护作用。BAT123对HIV-1LAI的gp120的第三个可变环具有特异性。当在病毒接种前1小时给予BAT123（1毫克/千克；25微克/小鼠）时，动物可免受LAI毒株的后续感染，但不能免受其他病毒毒株的感染。这导致抗体的血清峰值浓度达到16微克/毫升，这在人类中应该很容易达到。此外，在病毒接种后4小时内给予抗体时，可观察到暴露后保护作用。然而，当在感染确立后给予BAT123时，未观察到治疗效果。这些结果表明，在某些临床情况下，被动抗体预防HIV-1感染可能是可行的。
